These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. Lanes R; Soros A; Flores K; Gunczler P; Carrillo E; Bandel J J Clin Endocrinol Metab; 2005 Jul; 90(7):3978-82. PubMed ID: 15870123 [TBL] [Abstract][Full Text] [Related]
3. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Iacobellis G; Singh N; Wharton S; Sharma AM Obesity (Silver Spring); 2008 Jul; 16(7):1693-7. PubMed ID: 18451775 [TBL] [Abstract][Full Text] [Related]
4. [The effect of one year of recombinant human growth hormone (rhGH) therapy on left ventricle structure and function in adults with severe growth hormone deficiency]. Płońska E; Krzyzanowska-Swiniarska B; Gruszczyńska M; Pynka S; Lewandowski M; Kornacewicz-Jach Z; Pilarska K Pol Merkur Lekarski; 2006 Apr; 20(118):386-9. PubMed ID: 16886557 [TBL] [Abstract][Full Text] [Related]
5. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Janssen JA; van der Toorn FM; Hofland LJ; van Koetsveld P; Broglio F; Ghigo E; Lamberts SW; Jan van der Lely A Eur J Endocrinol; 2001 Dec; 145(6):711-6. PubMed ID: 11720895 [TBL] [Abstract][Full Text] [Related]
6. Growth hormone (GH) substitution for one year normalizes elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial. Fisker S; Vahl N; Hansen TB; Jørgensen JO; Hagen C; Orskov H; Christiansen JS Growth Horm IGF Res; 1998 Apr; 8(2):105-12. PubMed ID: 10987677 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]. Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383 [TBL] [Abstract][Full Text] [Related]
9. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P; Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692 [TBL] [Abstract][Full Text] [Related]
10. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. Christopher M; Hew FL; Oakley M; Rantzau C; Alford F J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675 [TBL] [Abstract][Full Text] [Related]
11. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127 [TBL] [Abstract][Full Text] [Related]
12. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. Janssen YJ; Doornbos J; Roelfsema F J Clin Endocrinol Metab; 1999 Jan; 84(1):279-84. PubMed ID: 9920096 [TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Natale F; Tedesco MA; Mocerino R; de Simone V; Di Marco GM; Aronne L; Credendino M; Siniscalchi C; Calabrò P; Cotrufo M; Calabrò R Eur J Echocardiogr; 2009 Jun; 10(4):549-55. PubMed ID: 19211568 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Losa M; Scavini M; Gatti E; Rossini A; Madaschi S; Formenti I; Caumo A; Stidley CA; Lanzi R Thyroid; 2008 Dec; 18(12):1249-54. PubMed ID: 19012473 [TBL] [Abstract][Full Text] [Related]
17. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults. Miljic D; Miljic P; Doknic M; Pekic S; Djurovic M; Colovic M; Popovic V Hormones (Athens); 2006; 5(3):187-91. PubMed ID: 16950752 [TBL] [Abstract][Full Text] [Related]
18. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170 [TBL] [Abstract][Full Text] [Related]
19. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. van der Klaauw AA; Romijn JA; Biermasz NR; Smit JW; van Doorn J; Dekkers OM; Roelfsema F; Pereira AM Eur J Endocrinol; 2006 Nov; 155(5):701-8. PubMed ID: 17062886 [TBL] [Abstract][Full Text] [Related]
20. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]